These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37821641)

  • 1. Anti-leukemia effects of omipalisib in acute myeloid leukemia: inhibition of PI3K/AKT/mTOR signaling and suppression of mitochondrial biogenesis.
    Tseng CY; Fu YH; Ou DL; Lu JW; Hou HA; Lin LI
    Cancer Gene Ther; 2023 Dec; 30(12):1691-1701. PubMed ID: 37821641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling.
    Zhu DS; Dong JY; Xu YY; Zhang XT; Fu SB; Liu W
    Med Sci Monit; 2020 Aug; 26():e927106. PubMed ID: 32804918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
    Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K
    Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of N-(2-chloro-5-(3-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) as a highly potent PI3K/mTOR dual inhibitor for the treatment of acute myeloid leukemia.
    Yang C; Chen Y; Wu T; Gao Y; Liu X; Yang Y; Ling Y; Jia Y; Deng M; Wang J; Zhou Y
    Eur J Med Chem; 2023 Oct; 258():115543. PubMed ID: 37329712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia.
    Kayabasi C; Yelken BO; Asik A; Okcanoglu TB; Sogutlu F; Gasimli R; Susluer SY; Saydam G; Avci CB; Gunduz C
    Eur J Pharmacol; 2021 Nov; 910():174446. PubMed ID: 34461124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
    Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
    Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insilco and Invitro approaches identify novel dual PI3K/AKT pathway inhibitors to control acute myeloid leukemia cell proliferations.
    Abohassan M; Alshahrani M; Alshahrani MY; Rajagopalan P
    Med Oncol; 2022 Oct; 39(12):249. PubMed ID: 36209300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
    Tabe Y; Tafuri A; Sekihara K; Yang H; Konopleva M
    Expert Opin Ther Targets; 2017 Jul; 21(7):705-714. PubMed ID: 28537457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual PI3K/mTOR inhibitor NVP‑BEZ235 decreases the proliferation of doxorubicin‑resistant K562 cells.
    Li J; Wang X; Ma C; Xu S; Xu M; Yang J; Wang R; Xue L
    Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 34223631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
    Weisberg E; Banerji L; Wright RD; Barrett R; Ray A; Moreno D; Catley L; Jiang J; Hall-Meyers E; Sauveur-Michel M; Stone R; Galinsky I; Fox E; Kung AL; Griffin JD
    Blood; 2008 Apr; 111(7):3723-34. PubMed ID: 18184863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison.
    Nepstad I; Hatfield KJ; Aasebø E; Hernandez-Valladares M; Brenner AK; Bartaula-Brevik S; Berven F; Selheim F; Skavland J; Gjertsen BT; Reikvam H; Bruserud Ø
    Expert Opin Ther Targets; 2018 Jul; 22(7):639-653. PubMed ID: 29889583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effects of PI3K/Akt/mTOR Signaling Pathway Inhibitors on the Expression of Immune Checkpoint Ligands in Acute Myeloid Leukemia Cell Line.
    Taghiloo S; Norozi S; Asgarian-Omran H
    Iran J Allergy Asthma Immunol; 2022 Apr; 21(2):178-188. PubMed ID: 35490271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pyridinesulfonamide derivative FD268 suppresses cell proliferation and induces apoptosis via inhibiting PI3K pathway in acute myeloid leukemia.
    Chen Y; Wu T; Yang C; Lu M; Chen Z; Deng M; Jia Y; Yang Y; Liu X; Wang H; Ling Y; Lu L; Zhou Y
    PLoS One; 2022; 17(11):e0277893. PubMed ID: 36413544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel iheyamine A derivative L42 suppresses acute myeloid leukemia via dual regulation of the PI3K/AKT/FOXO3a axis and TNF signaling pathway.
    Dinghuan W; Yi K; Jianzhi T; Wenfei W; Chunlin W; Anling H; Zhixu H; Ben-David Y; Sheng L; Xiaoyan Y; Xiao X
    Biomed Pharmacother; 2024 Aug; 177():117071. PubMed ID: 38981243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines.
    Hsin IL; Shen HP; Chang HY; Ko JL; Wang PH
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.
    Chiarini F; Lonetti A; Teti G; Orsini E; Bressanin D; Cappellini A; Ricci F; Tazzari PL; Ognibene A; Falconi M; Pagliaro P; Iacobucci I; Martinelli G; Amadori S; McCubrey JA; Martelli AM
    Oncotarget; 2012 Dec; 3(12):1615-28. PubMed ID: 23271044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells.
    Nepstad I; Hatfield KJ; Grønningsæter IS; Reikvam H
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prazosin inhibits the proliferation and survival of acute myeloid leukaemia cells through down-regulating TNS1.
    Sun X; Yang S; Song W
    Biomed Pharmacother; 2020 Apr; 124():109731. PubMed ID: 31954876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax.
    Liu H; Hussain Z; Xie Q; Yan X; Zeng C; Zhou G; Cao S
    Exp Cell Res; 2022 Aug; 417(2):113192. PubMed ID: 35568072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.